Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 9/11/2018
SIETES contiene 92577 citas

 
 
 1 a 20 de 325 siguiente >>
Presentar resultados
Seleccionar todas
2.Enlace a cita original Cita con resumen
Puthumana J, Wallach JD, Ross JS. Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation. JAMA 2018;319:17 de julio. [Ref.ID 102793]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Sénat M-V, Affres H, Letourneau A, Coustols-Valat M, Cazaubiel M, Legardeur H, Jacquier JF, Bourcigaux N, Simon E, Rod A, Héron I, Castera V, Sentilhes L, Bretelle F, Rolland C, Morin M, Deruelle P, De Carne C, Maillot F, Beucher G, Verspyck E, Desbriere R, Laboureau S, Mitanchez D, Bouyer J, for the Groupe de Recherche en Obstétrique et Gynécologie (GROG). Effect of glyburide vs subcutaneous insulin on perinatal complications among women with gestational diabetes. A randomized clinical trial. JAMA 2018;319:1 de junio. [Ref.ID 102766]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Coustan DR, Barbour L. Insulin vs glyburide for gestational diabetes. JAMA 2018;319:1 de junio. [Ref.ID 102765]
5.Enlace a cita original Cita con resumen
Palmer SC, Strippoli GFM. Metformin as first-line treatment for type 2 diabetes . Lancet 2018;392:14 de julio. [Ref.ID 102743]
6.Enlace a cita original Cita con resumen
Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 2018;391:30 de junio. [Ref.ID 102741]
9.Enlace a cita originalTiene citas relacionadas Cita con resumen
Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, on behalf of the show SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391:9 de junio. [Ref.ID 102692]
10.Enlace a cita originalTiene citas relacionadas Cita con resumen
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ, Wang Y, Lobo MD, Saxena M, Feyz L, Rader F, Lurz P, Sayer J, Sapoval M, Levy T, Sanghvi K, Abraham J, Sharp ASP, Fisher NDL, Bloch MJ, Reeve-Stoffer H, Coleman L, Mullin C, Mauri L, on behalf of the RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018;391:2335-45. [Ref.ID 102691]
11.Enlace a cita originalTiene citas relacionadas Cita con resumen
Blankestijn PJ, Bots ML. Renal denervation in uncontrolled hypertension: the story continues to unfold. Lancet 2018;391:9 de junio. [Ref.ID 102690]
12. Cita con resumen
Vaidya JS, Massarut S, Vaidya HJ, Alexander EC, Richards T, Caris JA, Sirohi B, Tobias JS. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ 2018;360:j5913. [Ref.ID 102449]
13. Cita con resumen
Habibi R, Lexchin J, Mintzes B, Holbrook A. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. Br J Clin Pharmacol 2017;83:2549-56. [Ref.ID 102116]
15.Tiene citas relacionadas Cita con resumen
Eunjung Cha A. Monthly shot could be the ‘next revolution’ in HIV therapy, replacing daily pills. The Washington Post 2017:1. [Ref.ID 101921]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Feuerstein A. STAT Plus: Strong results for a new HIV drug will be a big boost to Gilead Sciences. STAT 2017:24 de julio. [Ref.ID 101919]
17.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017;6:6 de junio. [Ref.ID 101674]
18.Tiene citas relacionadas Cita con resumen
Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection?. Lancet 2017;390:107-9. [Ref.ID 101668]
19.Tiene citas relacionadas Cita con resumen
Hawkes N. Are new hepatitis C drugs all they’re cracked up to be?. BMJ 2017;357:j2961. [Ref.ID 101659]
20. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
Seleccionar todas
 
 1 a 20 de 325 siguiente >>